Ghosh RK, Ghosh GC, Gupta M, et al. - Researchers performed this review to gain insights into the possible underlying molecular mechanisms as well as to analyze the evidence from existing trials concerning the heart failure (HF)-related outcomes associated with sodium-glucose co-transporter 2 (SGLT2) inhibitors. The FDA approved SGLT2 inhibitors, such as canagliflozin, empagliflozin, dapagliflozin, and ertugliflozin, have shown cardioprotective and renoprotective functions, in addition to their positive effect on blood glucose, in major trials such as EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI-58 and CREDENCE. SGLT2 inhibitors have been shown to reduce progression of nephropathy and HF readmission in the subgroup analysis from these major trials. In both diabetics and non-diabetics, dapagliflozin vs placebo demonstrated a significant decrease in mortality attributable to cardiovascular causes and hospitalization in HF in recently released phase III results from DAPA-HF trial.